Compare VZLA & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VZLA | MESO |
|---|---|---|
| Founded | 2017 | 2004 |
| Country | Canada | Australia |
| Employees | N/A | 81 |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.2B |
| IPO Year | 2019 | N/A |
| Metric | VZLA | MESO |
|---|---|---|
| Price | $3.56 | $14.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | ★ 9.0M | 242.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $644.56 |
| Revenue Next Year | N/A | $38.70 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.69 | $9.61 |
| 52 Week High | $7.19 | $21.50 |
| Indicator | VZLA | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 35.75 | 36.13 |
| Support Level | $3.35 | $14.35 |
| Resistance Level | $4.33 | $16.33 |
| Average True Range (ATR) | 0.22 | 0.56 |
| MACD | -0.00 | -0.06 |
| Stochastic Oscillator | 1.10 | 27.35 |
Vizsla Silver Corp is a junior mineral exploration and development company focused on advancing its Panuco silver-gold project located in Sinaloa, Mexico. The property contains quartz-carbonate veins with workings defining both steeply plunging and sub-horizontal ore shoots. Mineralization occurs as silver sulphides including argentite and acanthite, native gold, electrum and native silver associated with pyrite, minor galena, sphalerite and rare chalcopyrite. It has one operating segment, which is principally mineral exploration.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.